Harbour BioMed, a global biopharmaceutical company specializing in novel antibody therapeutics for immunology and oncology, announced a long-term strategic collaboration with Yantai Lannacheng Biotechnology to jointly develop next-generation radionuclide drug conjugates (RDCs).

 

RDCs, which deliver radionuclides directly to tumor lesions via tumor antigen–specific ligands, offer a targeted approach that spares healthy tissues. 

 

Unlike traditional antibody–drug conjugates (ADCs), RDCs can also affect neighboring tumor cells and the tumor microenvironment—even if those cells don’t express the target antigen—potentially overcoming tumor heterogeneity and drug resistance. The technology also holds promise for theranostics, integrating both diagnosis and treatment.

 

Harbour BioMed brings advanced antibody discovery platforms to the table. Its proprietary Harbour Mice platform generates fully human monoclonal antibodies in conventional (H2L2) and heavy chain-only (HCAb) formats, eliminating the need for humanization. HCAb antibodies are roughly half the size of conventional IgGs, offering superior tissue penetration, low immunogenicity, and high specificity—features that enhance RDC targeting and reduce side effects.

 

Founded in 2021, Lannacheng is a clinical-stage biotech focused on integrated theranostic radiopharmaceuticals for oncology. Its R&D capabilities include pharmacokinetic optimization, dual-targeting drug platforms, and radioisotope supply, supported by parent company Dongcheng Biochem. Lannacheng is also building a GMP production facility in Yantai, strengthening its capacity to advance a sustainable and scalable radiopharmaceutical pipeline.

 

Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, said: "We are very pleased to establish a long-term strategic collaboration with Lannacheng to jointly advance the development of next-generation RDCs. Harbour BioMed is committed to providing efficient and highly differentiated antibody solutions for innovative therapies through our globally leading Harbour Mice fully human antibody platform. 

 

"This collaboration will deeply integrate Harbour BioMed's expertise in antibody discovery with Lannacheng's strengths in radiopharmaceutical R&D and commercialization, accelerating the development of more precise, effective and safe cancer therapies and bringing new hope to patients worldwide."

 

Wu Xiaoming, General Manager of Lannacheng, added: "We are delighted to establish a long-term strategic collaboration with Harbour BioMed to jointly advance the R&D and translation of next-generation radiopharmaceuticals. 

 

"Lannacheng is committed to leveraging our systematic radiopharmaceutical technology platform, comprehensive industrial capabilities, and global collaboration network to provide efficient, innovative, and differentiated integrated solutions for tumor diagnosis and treatment. 

 

"This collaboration will fully combine Lannacheng's strengths in radiopharmaceutical R&D and commercialization and Harbour BioMed's deep expertise in antibody discovery. Together, we aim to accelerate the development of more precise, effective, and safe cancer treatment therapies, bringing new hope to patients worldwide."